# A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

> **NCT03022045** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 18 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** risankizumab

## Key facts

- **NCT ID:** NCT03022045
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-26
- **Primary completion:** 2017-09-17
- **Final completion:** 2020-11-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03022045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03022045, "A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03022045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*